Expert Guidance on Selecting First-line Therapy: Case-Based Discussion (33 mins)
  • CME

Gain perspective on how to choose among first-line regimens. Debate focuses on when to initiate ART, baseline HIV-1 RNA constraints and their effect on the kinetics of viral suppression, the drug–drug interaction potentials of commonly used ARVs, and the potential for weight gain during therapy.
Jean-Michel Molina, MD, PhD
Program Director
José R. Arribas, MD
Alexandra Calmy, MD, FMH, PhD
Laura Waters, FRCP, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: February 12, 2020 Expiration: February 11, 2021

This program is divided into short segments which you can review from the Activity landing page. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.

Editorial note: DHHS guidance had not been updated since October 2018 at the time of this recording. Faculty management decisions were, therefore, informed in part by that guidance document. The downloadable slideset that accompanies this module has been updated to reflect December 2019 DHHS guidance.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recent clinical trial data when devising patient care strategies that include newer ARV agents
  • Incorporate innovative ARV treatment strategies into the management of persons with HIV infection when appropriate
  • Appraise 2-drug vs 3-drug treatment strategies in the care of persons with HIV infection

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Jean-Michel Molina, MD, PhD

Head of the Department of Infectious Diseases
Saint-Louis Hospital, Assistance-Publique Hôpitaux de Paris
Paris, France
Professor of Infectious Diseases
University of Paris
Paris, France

Jean-Michel Molina, MD, PhD, has disclosed that he has received funds for research support from Gilead Sciences; consulting fees from Gilead Sciences, Merck, and ViiV Healthcare; and fees for non-CME/CE services from Janssen.

Faculty

José R. Arribas, MD

Research Director (HIV and Infectious Diseases)
Hospital La Paz. IdiPAZ.
Madrid, Spain

José R. Arribas, MD, has disclosed that he has received consulting fees from Aelix, Gilead Sciences, Janssen, Merck, Teva, and ViiV Healthcare and funds for research support from Gilead Sciences, Merck, and ViiV Healthcare.
Alexandra Calmy, MD, FMH, PhD

HIV/AIDS Unit Director
Infectious Diseases Division
Geneva University Hospitals
University of Geneva
Geneva, Switzerland

Alexandra Calmy, MD, FMH, PhD, has disclosed that she has received fees for non-CME/CE services from Gilead Sciences.
Laura Waters, FRCP, MD

Consultant Physician, HIV/GU Medicine
Mortimer Market Centre
CNWL NHS Trust
London, United Kingdom

Laura Waters, MD, has disclosed that she has received consulting fees from Cipla, Gilead Sciences, Janssen, Merck, Mylan, and ViiV Healthcare.

Staff

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no relevant conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals who provide care for patients with HIV infection.

Goal

The goal of this activity is to improve learners’ knowledge and competence regarding the integration of newer ARV regimens and paradigms into patient management strategies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 12, 2020, through February 11, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Download CCO slides reviewing guidelines, key studies, and individual considerations for optimizing the use of current ART regimens to treat HIV

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Babafemi Taiwo, MBBS
Released: July 6, 2020

Latest data from Protocol 011 study of islatravir plus doravirine maintenance therapy from AIDS 2020: Virtual reported by Clinical Care Options.

Released: July 5, 2020

Download free expert-authored slides reviewing a patient case and the data and guidance on HIV and COVID-19, including risk factors and treatment

Paul E. Sax, MD Released: July 1, 2020

Watch this short video log from CCO faculty Dr. Paul Sax on his experience caring for a patient with HIV and COVID-19 pneumonia

Paul E. Sax, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: July 1, 2020 Expired: June 30, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?